Journals / Molecular Imaging and Radionuclide Therapy / 2017 / Cilt: 26 - Sayı: 1

Pediatrik Hodgkin Lenfoma Hastalarında Tedavi Öncesi Florodeoksiglukoz Pozitron Emisyon Tomografi/Bilgisayarlı Tomografi Parametreleri ve Klinik Prognostik Faktörler Arasındaki İlişki

The Correlation Between Pre-treatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Parameters and Clinical Prognostic Factors in Pediatric Hodgkin Lymphoma

Pages
9–16
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also, SUVbsa and SUVlbm may be better markers than SUVweight in the quantitative evaluation of FDG PET/CT scans in pediatric patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare standardized uptake values (SUV) derived from pre-treatment 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging and clinical prognostic factors in pediatric patients with Hodgkin lymphoma (HL).Methods: Pre-treatment FDG PET/CT findings of 28 children with HL were evaluated in this retrospective study.
📊
Key Findings & Data:These metabolic parameters were correlated with clinical factors [age, sex, number of lymph node groups, presence of splenic involvement, bulky mediastinal disease, Ann Arbor stage, serum white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), serum albumin and hemoglobin levels].Results: SUVbsa, SUVlbm, SUVweight, SUVglucose and MTV were higher in patients with stage III-IV disease, bulky tumor and >=3 lymph node groups (p<0.05).
💡
Conclusion & Impact:Also, SUVbsa and SUVlbm may be better markers than SUVweight in the quantitative evaluation of FDG PET/CT scans in pediatric patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To compare standardized uptake values (SUV) derived from pre-treatment 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging and clinical prognostic factors in pediatric patients with Hodgkin lymphoma (HL).Methods: Pre-treatment FDG PET/CT findings of 28 children with HL were evaluated in this retrospective study. Metabolic tumor volume (MTV), SUVmax normalized by weight (SUVweight), lean body mass (SUVlbm), body surface area (SUVbsa) and plasma glucose levels of tumors (SUVglucose) were calculated using pre-treatment FDG PET/CT scan images. These metabolic parameters were correlated with clinical factors [age, sex, number of lymph node groups, presence of splenic involvement, bulky mediastinal disease, Ann Arbor stage, serum white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), serum albumin and hemoglobin levels].Results: SUVbsa, SUVlbm, SUVweight, SUVglucose and MTV were higher in patients with stage III-IV disease, bulky tumor and >=3 lymph node groups (p<0.05). SUVbsa and SUVglucose were higher in patients with splenic involvement (p<0.05). There was no significant correlation between these metabolic parameters and sex, ESR, levels of albumin and WBC (p>0.05). SUVbsa and SUVlbm were higher in patients with anemia (p<0.05). Additionally, significant increases were detected in SUVweight, MTV, and SUVglucose with increasing age (p=0.005, p=0.027, and p=0.009, respectively). SUVbsa and SUVlbm had no significant correlation with age (p>0.05).Conclusion: Metabolic parameters derived from pre-treatment FDG PET/CT may have an important role in predicting highrisk disease in patients with HL. Also, SUVbsa and SUVlbm may be better markers than SUVweight in the quantitative evaluation of FDG PET/CT scans in pediatric patients.

Özet

Amaç: Hodgkin lenfoma (HL) tanısı konmuş çocuk hastalarda klinik prognostik faktörler ile tedavi öncesi 18F-florodeoksiglukoz (FDG) pozitron emisyon tomografi/bilgisayarlı tomografi (PET/BT) görüntülemeden elde edilen standart tutulum değerlerini (SUV) karşılaştırmaktır.Yöntem: Bu retrospektif çalışmada HL tanılı 28 çocuk hastanın FDG PET/BT bulguları değerlendirildi. Metabolik tümör volümü (MTV), kiloya (SUVkilo), yağsız vücut kitlesine (SUVlbm), vücut yüzey alanına (SUVbsa) and plazma glukoz seviyesine (SUVglukoz) göre normalize edilmiş SUVmaks değerleri tedavi öncesi FDG PET/CT görüntüleri kullanılarak hesaplandı. Bu metabolik parametrelerin klinik faktörler [yaş, cinsiyet, lenf nodu grup sayısı, dalak tutulumu, büyük mediastinal hastalık, Ann Arbor evreleme, serum lökosit sayımı (WBC), eritrosit sedimentasyon hızı (ESH), serum albumin ve hemoglobin seviyesi] ile ilişkisi araştırıldı.Bulgular: SUVbsa, SUVlbm, SUVkilo, SUVglukoz ve MTV evre 3-4 hastalığı, büyük tümörü ve >=3 lenf nodu grubu olan hastalarda daha yüksekti (p 0,05). SUVbsa ve SUVlbm anemisi olan hastalarda daha yüksekti (p 0,05).Sonuç: HL tanılı hastalarda tedavi öncesi FDG PET/BT'den elde edilen metabolik parametreler yüksek riskli hastalığı tahmin etmede önemli bir rol oynayabilir. Ayrıca, pediatrik hastalarda FDG PET/BT'nin kantitatif değerlendirilmesinde SUVbsa ve SUVlbm, SUVkilo'dan daha iyi belirteç olabilir.

🔖

Cite This Article

TATCI, E., BİNER, İ. U., EMİR, S., TANYILDIZ, H. G., ÖZMEN, Ö., ALAGÖZ, E., Gökçek, A., ŞAHİN, G. (2017). Pediatrik Hodgkin Lenfoma Hastalarında Tedavi Öncesi Florodeoksiglukoz Pozitron Emisyon Tomografi/Bilgisayarlı Tomografi Parametreleri ve Klinik Prognostik Faktörler Arasındaki İlişki. Molecular Imaging and Radionuclide Therapy, Cilt: 26 - Sayı: 1, 9–16. https://ajindex.com/articles/295109

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987;5:27-37
  2. Carde P, Burgers JM, Henry-Amar M, Hayat M, Sizoo W, Van der Schuer en E, Monconduit M, Noordijk EM, Lustman-Marechal J, Tanguy A, et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988;6:239-252
  3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514
  4. Tatsumi M, Miller JH, Wahl RL. 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies. J Nucl Med 2007;48:1923- 1931
  5. Depas G, De Barsy C, Jerusalem G, Hoyoux C, Dresse MF, Fassotte MF, Paquet N, Foidart J, Rigo P, Hustinx R. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 2005;32:31-38
  6. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-116
  7. Stauss J, Franzius C, Pfluger T, Juergens KU, Biassoni L, Begent J, Kluge R, Amthauer H, Voelker T, Højgaard L, Barrington S, Hain S, Lynch T, Hahn K. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging 2008;35:1581- 1588
  8. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 2010;195:310-320
  9. Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994;35:164-167
  10. Sager S, Asa S, Yilmaz M, Uslu L, Vatankulu B, Halaç M, Sönmezoglu K, Kanmaz B. Prognostic significance and predictive performance of volume-based parameters of F-18 FDG PET/CT in squamous cell head and neck cancers. J Cancer Res Ther 2014;10:922-926
  11. Park GC, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advancedstage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol 2013;24:208-214
  12. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and prac